Nektar Therapeutics (NKTR)
57.74
-1.04
(-1.77%)
USD |
NASDAQ |
Dec 10, 16:00
57.66
-0.08
(-0.14%)
After-Hours: 20:00
Nektar Therapeutics Cash from Investing (Quarterly): -94.87M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -2.983B |
| Amicus Therapeutics, Inc. | -1.299M |
| Regeneron Pharmaceuticals, Inc. | -402.90M |
| Rigel Pharmaceuticals, Inc. | -33.18M |
| Zevra Therapeutics, Inc. | -4.576M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -48.76M |
| Cash from Financing (Quarterly) | 141.68M |
| Free Cash Flow | -190.35M |
| Free Cash Flow Per Share (Quarterly) | -2.580 |
| Free Cash Flow to Equity (Quarterly) | -39.22M |
| Free Cash Flow to Firm (Quarterly) | -42.83M |
| Free Cash Flow Yield | -5.11% |